Ad5-nCoV

Adenovirus type-5 vector-based vaccine for COVID-19 · CanSino Biologics

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Ad5-nCoV, covering 2022-04-06 to 2025-06-25. Get the full timeline:

Most recent: Clinical Trial Update: Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV [Phase 2]

See pricing